CAH$214.05

Cardinal Health, Inc. demonstrates a mixed but generally improving financial trajectory. Revenue growth has been robust, albeit with a recent deceleration to -1.87% in FY2025 before rebounding to 10.08% TTM. Net income has seen significant recovery, climbing from a substantial loss in FY2022 to a strong positive in FY2025 and TTM, indicating improved bottom-line translation. Margins have shown positive trends, with operating margin expanding from -0.33% to 1.02% and TTM 1.04%, suggesting better operational efficiency. The major dip in FY2022's operating income (-$607M) and net income (-$938M) was a significant one-time event, making the subsequent rebound impressive. Assuming this is a healthcare distribution company, these margin improvements are positive, although absolute margins remain relatively thin for the sector. Risks include the slight revenue contraction in FY2025, which warrants close monitoring for sustained impact, and the volatility in operating and net income in prior years.

Cardinal Health's balance sheet exhibits concerning trends. While total current assets have shown modest growth to $36,373 million (TTM $39,230 million), this is outpaced by an increase in total current liabilities, reaching $38,897 million (TTM $43,314 million). This indicates potential liquidity strain. Total liabilities have steadily risen, now at $55,756 million (TTM $60,783 million), significantly overshadowing total assets of $53,122 million (TTM $58,083 million). Critically, shareholders' equity has been negative since FY 2022, currently at -$3,417 million (TTM -$4,155 million), and tangible book value is deeply negative, signaling a structural imbalance. The rising total debt, now $8,527 million (TTM $9,027 million), and negative net cash position further exacerbate solvency concerns.

Cardinal Health's operating cash flow (OCF) has shown significant volatility, with a TTM OCF of $6.099 billion, markedly higher than the latest FY's $2.397 billion, indicating strong recent performance following a sharp FY25 decline. Free cash flow (FCF) also mirrors this trend, with TTM FCF at $5.502 billion after a substantial drop in FY25. Capital expenditures have been consistently negative, around the $500-600 million range annually, suggesting ongoing reinvestment. However, large payments for business acquisitions, especially $5.250 billion in FY25 and $1.190 billion in FY24, are a major draw on cash. Capital allocation includes consistent dividends paid and significant share repurchases, although net long-term debt has increased in recent periods, partially offsetting these returns.

Cardinal Health's liquidity profile shows a concerning trend. The Current Ratio has steadily declined from 1.12 in FY2021 to 0.91 currently, indicating a weakening ability to cover short-term liabilities. The Quick Ratio has also fallen, from 0.45 to 0.38, highlighting a similar challenge. Leverage metrics present mixed signals. While the Debt/EBITDA ratio has significantly improved from 62.53 to 2.64, the Net Debt/Equity Ratio has moved from negative to slightly positive, then negative again, suggesting some volatility. Efficiency ratios, particularly Inventory Turnover, show improvement, rising from 11.2 to 12.73, indicating better inventory management. Asset Turnover has also generally improved. Profitability and returns are inconsistent; ROE has been highly volatile, including negative figures, while ROIC has improved from -6.15% to 17.6%. Overall, the company's financial health presents a mixed picture with notable liquidity challenges despite some improvements in efficiency and recent profitability trends.

Cardinal Health exhibits a robust growth trajectory, transitioning from historical revenue growth averaging around 10% between FY2021 and FY2024 to an impressive estimated 17.38% in FY2026, despite a projected -1.87% dip in FY2025. This fluctuation in FY2025 is an anomaly amid otherwise strong positive growth. EPS demonstrates a significant recovery and acceleration, moving from negative values in FY2022 to estimated double-digit growth rates in subsequent years, culminating in a projected 61.37% in FY2026 and 12.35% in FY2027. The forward P/E ratios of 20.57 for FY2026 and 18.31 for FY2027 appear reasonable given the strong earnings growth outlook. Analyst sentiment is overwhelmingly positive, with a "Buy" consensus rating based on 11 analysts and a tight recommendation trend holding stable with a majority of "Buy" and "Strong Buy" ratings, indicating high conviction.